Clinical Trials · NCT01279915

A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects

CompletedPhase 1Linaclotide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Astellas Pharma Inc
Enrollment
32
Start date
Oct 2010
Locations
1 site, Japan
Primary endpoint
Pharmacokinetics of ASP0456 assessed by its plasma concentration change
View Linaclotide compound reference